Good news!
This is another nice example how government intervention did more harm than good!
"Pharma, biotechnology companies and investors are renewing their interest in osteoporosis treatments, incentivized by a regulatory change that makes bone health trials easier to run, at least in the United States.
Drug developers can now seek regulatory approval for a drug that increases bone density, rather than needing to prove the drug reduces bone breakages. Companies are aiming for drugs devoid of the fracture risk that historically plagued the field, with biotechs such as Skeletalis, EnteraBio and Angitia entering the osteoporosis field. ..."
Drugmakers, biotech VCs show ‘reinvigorated’ interest in osteoporosis treatments "Shift by the FDA and frustration with existing therapies have created new opportunities"
No comments:
Post a Comment